Price Target Changed • Aug 13
Price target increased by 12% to US$7.40 Up from US$6.58, the current price target is an average from 6 analysts. New target price is 363% above last closing price of US$1.60. Stock is down 48% over the past year. The company is forecast to post a net loss per share of US$0.38 next year compared to a net loss per share of US$0.50 last year. New Risk • Aug 12
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Announcement • Aug 12
Codexis, Inc. Reaffirms Earnings Guidance for the Full Year 2026 Codexis, Inc. reaffirmed earnings guidance for the full year 2026. For the period, the company continues to expect revenues to be in the range of $72 million to $76 million. New Risk • Aug 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 30% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Announcement • Aug 04
Codexis, Inc. Announces Strategic Advisory Board Changes Codexis, Inc. announced the appointment of David Butler, PhD, to its Strategic Advisory Board. Dr. Butler will provide technical guidance, industry expertise, and strategic insight to support Codexis’ ongoing growth, innovation and core mission. David Butler has over 20 years of experience in the oligonucleotide field, most recently serving as Chief Technology Officer with Hongene Biotech Corporation from 2023 to 2026. Prior to Hongene, he led chemistry organizations at Wave Life Sciences, Korro Bio, and Alltrna. Earlier in his career at Alnylam, he contributed to the development of liquid nanoparticle (LNP) delivery technologies, the foundation for today’s mRNA-based therapeutics and vaccines. He holds a BSc and PhD in Chemistry from St. Andrews University. Codexis, Inc. also announced that Carole Cobb will be stepping down from the Strategic Advisory Board. Announcement • Jul 28
Codexis, Inc. to Report Q2, 2026 Results on Aug 11, 2026 Codexis, Inc. announced that they will report Q2, 2026 results After-Market on Aug 11, 2026 Announcement • Jul 25
Codexis, Inc. has completed a Follow-on Equity Offering in the amount of $25.000001 million. Codexis, Inc. has completed a Follow-on Equity Offering in the amount of $25.000001 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 16,666,667
Price\Range: $1.5
Discount Per Security: $0.09 New Risk • Jul 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • May 22
Codexis Inc Highlights Stereochemistry Advances for Scalable RNA Manufacturing At Tides USA Codexis, Inc. shared new advances in RNA therapeutic manufacturing at TIDES USA 2026 at the Hynes Convention Center in Boston. Through presentations and a panel discussion, the Company highlighted how its ECO Synthesis Manufacturing Platform is advancing the production of siRNA, now enabling stereochemical control while addressing key industry challenges in scalability and sustainability. At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control of phosphorothioate stereochemistry using its ECO Synthesis platform. Stereochemistry—the three-dimensional arrangement of atoms within a molecule—plays an important role in how oligonucleotide therapeutics perform, influencing their efficacy and product quality. During Codexis’ expert panel, “Stereochemistry Control in RNAi Manufacturing: Signal or Noise?”, drug development leaders from Corsera Health, Arrowhead Pharmaceuticals, and Wave Life Sciences emphasized that stereochemical control is an important—and increasingly necessary—factor in advancing next-generation RNA therapeutics in order to optimize potency, and potentially enable novel dosage forms using higher concentrations of active pharmaceutical ingredient. Codexis also announced a new advancement for its ECO Synthesis platform: the ability to initiate enzymatic RNA synthesis starting from a single nucleotide. This will eliminate the need for a chemically-synthesized starter oligonucleotide, commonly used to initiate enzymatic nucleotide additions. This advancement is particularly important for the increasingly popular practice of ligating fragments into a complete siRNA molecule. The ability to make fully enzymatic fragments, together with highly engineered, highly efficient ligases such as those developed by Codexis, present a future state optimal production strategy for siRNA. Codexis shared sustainability data, showing the ECO Synthesis platform achieved more than a 50% reduction in global warming potential compared to conventional synthetic approaches. The company reported approximately 2.7-fold lower global warming potential on an input materials basis, driven in part by reduced organic solvent use and aqueous processing. Ligation and stereochemical control are becoming increasingly important as the RNA therapeutics field matures. The aqueous production of the ECO Synthesis Manufacturing Platform together with the potential to eliminate purification steps when using ligation strategies result in both superior process and environmental efficiency. Codexis continues to advance its ECO Synthesis platform as part of its broader strategy to discover and industrialize scalable manufacturing solutions for complex RNA therapeutics. Price Target Changed • May 11
Price target decreased by 7.1% to US$6.58 Down from US$7.08, the current price target is an average from 6 analysts. New target price is 148% above last closing price of US$2.65. Stock is up 0.4% over the past year. The company is forecast to post a net loss per share of US$0.40 next year compared to a net loss per share of US$0.50 last year. Reported Earnings • May 11
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$0.096 loss per share (improved from US$0.25 loss in 1Q 2025). Revenue: US$15.2m (up 102% from 1Q 2025). Net loss: US$8.70m (loss narrowed 58% from 1Q 2025). Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 27%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Apr 30
Codexis, Inc., Annual General Meeting, Jun 17, 2026 Codexis, Inc., Annual General Meeting, Jun 17, 2026. Breakeven Date Change • Apr 26
No longer forecast to breakeven The 7 analysts covering Codexis no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$20.0m in 2028. New consensus forecast suggests the company will make a loss of US$1.11m in 2028. Announcement • Apr 23
Codexis, Inc. to Report Q1, 2026 Results on May 07, 2026 Codexis, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026 Reported Earnings • Mar 12
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$0.51 loss per share (improved from US$0.89 loss in FY 2024). Revenue: US$70.4m (up 19% from FY 2024). Net loss: US$44.0m (loss narrowed 33% from FY 2024). Revenue exceeded analyst estimates by 4.6%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Announcement • Mar 12
Codexis, Inc. Provides Earnings Guidance for Full Year 2026 Codexis, Inc. provided earnings guidance for full year 2026. The company expects total revenues are expected to be in the range of $72 million to $76 million. Announcement • Feb 25
Codexis, Inc. to Report Q4, 2025 Results on Mar 11, 2026 Codexis, Inc. announced that they will report Q4, 2025 results After-Market on Mar 11, 2026 New Risk • Feb 24
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$96.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$62m). Market cap is less than US$100m (US$96.6m market cap). Breakeven Date Change • Feb 06
Forecast to breakeven in 2028 The 6 analysts covering Codexis expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$20.0m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Board Change • Feb 06
High number of new directors There are 6 new directors who have joined the board in the last 3 years. President, CEO & Director Alison Moore was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 23
Codexis, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Codexis, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Reported Earnings • Aug 14
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: US$0.15 loss per share (improved from US$0.32 loss in 2Q 2024). Revenue: US$15.3m (up 92% from 2Q 2024). Net loss: US$13.3m (loss narrowed 42% from 2Q 2024). Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Announcement • Jul 31
Codexis, Inc. to Report Q2, 2025 Results on Aug 13, 2025 Codexis, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025 Announcement • May 22
Codexis, Inc. Presents Data at the Tides USA Annual Meeting in San Diego, California Codexis, Inc. presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demonstrating the potential to control stereochemistry. During an oral Main Stage presentation, Codexis used inclisiran as an example to showcase how the use of mobilized enzymes in its ECO Synthesis platform delivers a consistent process with improved performance. Using sequential enzymatic synthesis, company: Continued to achieve consistent coupling efficiency of >98% Maintained the delivery of high product quality; Successfully decreased average cycle time by approximately 24%, translating into reduced production time; Demonstrated high yields of 30 grams of siRNA per liter. Using Codexis' ligase to manufacture siRNA, company data demonstrated the potential to reduce or eliminate costly downstream purification steps. This benefit of ligation has led many companies to explore using this method in siRNA manufacturing. The company's poster presentation highlighted how the Company's recently launched machine learning tool is improving the success rate of ligation to produce siRNA. The tool aids process design by guiding the selection of optimal pairings of ligases and RNA fragments and has been shown to significantly outperform traditional fragment selection by four to sixfold. By accelerating the ligase selection process and maximizing ligation efficiency, this tool demonstrates the potential to reduce process development time, lower costs, and enable an efficient manufacturing process for customers. Three CDMO Collaborator Presentations feature the Use of Codexis Ligases to Combine Short RNA Fragments: In addition to Codexis' presentations, Bachem, Nitto Avecia, and ST Pharm, three leading CDMOs in siRNA manufacturing, presented data on the use of Codexis ligases to successfully combine short RNA fragments. In a separate TIDES Talk presentation, Codexis highlighted a new feature under development for the ECO Synthesis technology to allow for stereochemical control during oligonucleotide synthesis. In contrast, the data in this oral presentation demonstrate how the ECO Synthesis platform can enable control over stereochemistry under process-relevant conditions. New Risk • May 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$60m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$60m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.9m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Reported Earnings • May 15
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$0.25 loss per share (further deteriorated from US$0.17 loss in 1Q 2024). Revenue: US$7.54m (down 56% from 1Q 2024). Net loss: US$20.7m (loss widened 80% from 1Q 2024). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 5.4%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings. Announcement • May 15
Codexis, Inc. Reiterates Earnings Guidance for Full-Year 2025 Codexis, Inc. Reiterated earnings guidance for full-year 2025. The company expects total revenues to be in the range of $64 million to $68 million. Announcement • May 01
Codexis, Inc. to Report Q1, 2025 Results on May 14, 2025 Codexis, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025 Announcement • Apr 28
Codexis, Inc., Annual General Meeting, Jun 10, 2025 Codexis, Inc., Annual General Meeting, Jun 10, 2025. Announcement • Apr 10
Codexis, Inc. Announces Retirement of Byron L. Dorgan as Director On April 4, 2025, Byron L. Dorgan provided notice to the board of directors of Codexis, Inc. of his intention to retire and not to stand for reelection to the Board at the expiration of his current term at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). Mr. Dorgan’s decision not to stand for reelection is not the result of any disagreement with the Company on any matter relating to its operations, policies, practices or otherwise. Mr. Dorgan will remain a director until the 2025 Annual Meeting. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board. Announcement • Apr 01
Codexis, Inc. Appoints Cynthia Collins to the Board of Directors Codexis, Inc. announced the appointment of Cynthia Collins to the company’s board of directors. Cynthia Collins is a recognized leader with more than four decades of experience working in the pharmaceutical and biotech industry. She currently serves as Executive Chair and interim CEO of Nutcracker Therapeutics, a contract, research, development and manufacturing organization with a next generation RNA precision manufacturing platform. Previously, she was the CEO of Editas Medicine, a premier CRISPR company where she oversaw the first clinical trial administration of an in vivo CRISPR gene editing therapy. Her other notable roles include CEO of Human Longevity, CEO and general manager of various life science businesses at GE Healthcare, CEO of GenVec, group vice president at Beckman Coulter, CEO of Sequoia Pharmaceuticals, and president of oncology at Baxter Healthcare. Ms. Collins also currently serves as a board member at Certara, MaxCyte, DermTech, Alanis Therapeutics, Draper Laboratories, and Foundation for mRNA Medicines. She holds a bachelor’s degree in microbiology from the University of Illinois Urbana-Champaign and an MBA from the University of Chicago Booth School of Business. Breakeven Date Change • Mar 07
Forecast to breakeven in 2027 The 7 analysts covering Codexis expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 25% per year to 2026. The company is expected to make a profit of US$5.11m in 2027. Average annual earnings growth of 56% is required to achieve expected profit on schedule. New Risk • Mar 03
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$65m Forecast net loss in 3 years: US$6.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$6.6m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Mar 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Breakeven Date Change • Feb 28
Forecast to breakeven in 2027 The 7 analysts covering Codexis expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 23% per year to 2026. The company is expected to make a profit of US$5.11m in 2027. Average annual earnings growth of 58% is required to achieve expected profit on schedule. Announcement • Feb 28
Codexis, Inc. Provides Earnings Guidance for 2025 Codexis, Inc. provided earnings guidance for 2025. The company expects total revenues to be in the range of $64 million to $68 million. Announcement • Feb 14
Codexis, Inc. to Report Q4, 2024 Results on Feb 27, 2025 Codexis, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 27, 2025 Announcement • Feb 09
Codexis, Inc. Appoints Arthur Levin to Strategic Advisory Board Codexis, Inc. announced the appointment of Arthur Levin, PhD, to the Company’s Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform. In addition to his role on the Board of Directors, Dr. Levin previously held the positions of Distinguished Scientist, Strategic Leader and Chief Scientific Officer at Avidity. Dr. Levin is a highly regarded key opinion leader in the RNA therapeutics field who has led teams responsible for the development of many oligonucleotides. Prior to joining Avidity, Dr. Levin was the Executive Vice President of Research and Development at miRagen Therapeutics and held senior drug development roles at Ionis (formerly Isis) Pharmaceuticals and Santaris Pharmaceuticals. He has published more than 100 scientific articles and has authored several of the most cited reviews in the field. In addition to Codexis, he serves on the scientific advisory boards of multiple institutions. Dr. Levin received a doctorate in toxicology from the University of Rochester and holds a bachelor’s degree in biology from Muhlenberg College. Buy Or Sell Opportunity • Jan 27
Now 22% undervalued Over the last 90 days, the stock has risen 48% to US$4.72. The fair value is estimated to be US$6.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has declined by 46%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 48% per annum over the same time period. Announcement • Jan 17
Codexis, Inc. Appoints Christos Richards to Board of Directors Codexis, Inc. announced the appointment of Christos Richards to the Company’s Board of Directors. Christos Richards brings over 30 years of global executive advisory and search experience for the biopharmaceutical and healthcare industry to Codexis. To date, he has completed more than 450 executive level assignments, including over 200 Board, CEO and CEO succession projects in the Life Sciences sector. He currently serves as Global Head of Healthcare and Life Sciences at Calibre One, a global executive search firm with offices across California as well as Chicago, New York and London. Mr. Richards serves clients from venture-backed startups to leading global enterprises in devices, diagnostics, agricultural biotechnology, animal health, tools, services and digital health sectors. He has spent 20 years as a partner with two prominent boutique search firms, including serving as Chief Executive Officer of Levin & Company. Mr. Richards previously served on the Board of Directors for Coherus BioSciences and is also an advisor for the University of California, San Francisco Innovation Ventures Entrepreneurship Center. He holds a diploma in hospitality management from Schweizerische Wirteschule in Lucerne/Davos, Switzerland. Buy Or Sell Opportunity • Jan 08
Now 22% undervalued Over the last 90 days, the stock has risen 60% to US$4.76. The fair value is estimated to be US$6.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has declined by 46%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 48% per annum over the same time period. Announcement • Nov 15
Codexis, Inc. Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics Codexis, Inc. announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company’s rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform and establish Codexis’ position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics. During an oral Spotlight Presentation, Codexis unveiled the successful end-to-end enzymatic synthesis of an entire approved siRNA therapeutic asset, inclisiran. Codexis enzymatically synthesized the full-length sense and antisense strands of the molecule, including the enzymatic incorporation of a tissue-targeting moiety to the sense strand. To date, this process has only been completed utilizing phosphoramidite chemistry, a process that involves the use of harsh chemical conditions and vast amounts of toxic organic solvents. By contrast, Codexis’ ECO Synthesis manufacturing platform operates under milder, aqueous conditions, that improves product quality and dramatically decreases chemical waste production. In addition to this fully enzymatic route of synthesis, the Company demonstrated similar outcomes utilizing three routes of enzymatic ligation to produce the siRNA therapeutic asset, combining oligonucleotide fragments made by sequential enzymatic synthesis and traditional phosphoramidite chemistry. Key data from the presentation include: Achieved incorporation efficiency of >98% during sequential enzymatic oligo synthesis. Successfully attached the tri-GalNAc tissue-targeting moiety by enzymatic ligation. Obtained full-length oligonucleotides of equal quality and yields, using ligation of short fragments made with enzymes or by traditional phosphoramidite chemistry. Now that Codexis has successfully achieved this unprecedented milestone, the Company will continue to optimize its process for robustness, scaled-up quantities and improved purity with the goal of providing customers with siRNA material of comparable or better quality to phosphoramidite chemistry. The Company anticipates ramping up manufacturing of siRNA in quantities for preclinical testing following the successful build out of its ECO Synthesis Innovation Lab at the end of this year. Two additional presentations focused on results of direct comparisons of Codexis’ engineered double-stranded RNA (dsRNA) ligases and wild-type (WT) enzymes when used to combine short oligonucleotide fragments to synthesize full-length siRNA therapeutic compounds. In a joint poster with Bachem, one of the world’s leading CDMOs in oligonucleotide manufacturing, the data provided compelling external validation of the superior performance of Codexis ligases over existing wild-type enzymes in use today. Codexis enzymes demonstrated superior performance over wild-type enzymes across both volumetric productivity and substrate versatility. These dsRNA ligases outperformed on multiple substrate designs and enabled a higher conversion rate of oligonucleotide fragments into siRNA at increased concentrations of raw materials. In a separate TIDES Talk presentation, Codexis demonstrated improved performance of its dsRNA ligase over WT enzymes based on real customer case studies executed through the Company’s RNA Ligase Screening and Optimization Services, launched in May 2024. Codexis’ engineered ligases delivered robust, in-process performance, including higher substrate loading, faster reaction times and improved conversation at elevated temperatures. These data demonstrate the Company’s ability to accelerate delivery of lead ligase variants to customers and optimize process conditions for a customer’s specific asset. Announcement • Nov 13
Codexis, Inc. Appoints Raymond De Vré to Board of Directors Codexis, Inc. announced the appointment of Raymond De Vré, PhD, to the Company’s Board of Directors. Dr. De Vré brings over 20 years of executive-level experience to Codexis. He currently serves as Managing Director at RADV Advisory, an independent strategic and operational advisory company focused on investments in the global healthcare and contract development and manufacturing organization (CDMO) space. Prior to founding RADV Advisory, he was the Chief Executive Officer of PolyPeptide Group, a CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally. Prior to PolyPeptide, Dr. De Vré held multiple senior leadership roles at Dr. Reddy’s Laboratories, including Senior Vice President, Head of Biologics, and served as a member of the Management Council. Earlier in his career, he was a Partner at McKinsey & Company, working mostly in the pharmaceutical and biotech practice. Dr. De Vré holds a PhD in Applied Physics from Stanford University and a master’s degree in engineering from Université Libre de Bruxelles. New Risk • Nov 04
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Reported Earnings • Nov 01
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: US$0.29 loss per share (improved from US$0.50 loss in 3Q 2023). Revenue: US$12.8m (up 38% from 3Q 2023). Net loss: US$20.6m (loss narrowed 41% from 3Q 2023). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Announcement • Oct 11
Codexis, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Codexis, Inc. announced that they will report Q3, 2024 results After-Market on Oct 31, 2024 Announcement • Oct 03
Codexis, Inc. Announces Executive Changes Codexis, Inc. announced an increase in its cash reserves through capital raises totaling $31 million via the Company’s existing at-the-market facility during the quarter ended September 30, 2024. In addition to the financing, the Company strengthened its management team through the appointments of Alison Moore, PhD, to the newly created role of Chief Technology Officer. The Company also announced the appointment of John Schiffhauer as Senior Vice President of Intellectual Property. Mr. Schiffhauer brings over 20 years of experience in legal operations and intellectual property at Intel, and most recently, Zymergen, to this newly created role focused on managing the Company’s complex IP portfolio and executing strategic partnerships around it. Alison Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing. She is former Chief Technical Officer of Allogene Therapeutics, a pioneering clinical-stage company advancing CAR-T therapies. Prior to Allogene, she spent a total of 20 years at Amgen, most recently as Senior Vice President, Process Development, and including roles in Supply Chain and Manufacturing. Dr. Moore also has experience at Genentech as a Director in Chemistry, Manufacturing and Controls, and in Regulatory Affairs. Dr. Moore holds a bachelor’s degree in pharmacology with honors and a doctorate degree in cell biology from Manchester University, England. Major Estimate Revision • Aug 19
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.676 to -US$0.755 per share. Revenue forecast unchanged at US$65.1m. Life Sciences industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$7.17 unchanged from last update. Share price rose 6.7% to US$3.01 over the past week. Major Estimate Revision • Aug 15
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.676 to -US$0.75 per share. Revenue forecast unchanged at US$65.2m. Life Sciences industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$7.43 unchanged from last update. Share price fell 11% to US$2.81 over the past week. Reported Earnings • Aug 09
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: US$0.32 loss per share (further deteriorated from US$0.17 loss in 2Q 2023). Revenue: US$7.98m (down 63% from 2Q 2023). Net loss: US$22.8m (loss widened 98% from 2Q 2023). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year and the company’s share price has also fallen by 51% per year. Announcement • Aug 09
Codexis, Inc. Reiterates Earnings Guidance for the Full Year 2024 Codexis, Inc. reiterated earnings guidance for the full year 2024. For the year, Product revenues are expected to be in the range of $38 million to $42 million, excluding revenue related to PAXLOVID. Announcement • Jul 19
Codexis, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Codexis, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 Announcement • Jul 02
Codexis, Inc. (NasdaqGS:CDXS) entered into an asset purchase agreement to acquire Gene Therapy Assets of Crosswalk Therapeutics. Codexis, Inc. (NasdaqGS:CDXS) entered into an asset purchase agreement to acquire Gene Therapy Assets of Crosswalk Therapeutics on July 1, 2024. Announcement • May 15
Codexis, Inc. Presents Enzymatic Synthesis Data at TIDES USA Annual Meeting and Launches RNA Ligase Screening and Optimization Services Codexis, Inc. announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented on May 14, 2024 in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024. Codexis Enzymatically Synthesizes Fully Modified RNA Oligonucleotide: During the presentation, Codexis will showcase data on the enzymatic synthesis of a known siRNA oligonucleotide that incorporates the nucleotide modifications most frequently found in approved therapeutic assets today. This includes the synthesis of siRNA compounds using the Company’s Enzyme Catalyzed Oligonucleotide (ECO) Synthesis manufacturing platform from a starter oligonucleotide to the inclusion of a conjugation moiety. This final step primes the oligonucleotide for the attachment of a customer’s proprietary targeting moiety to enable direct delivery of the therapeutic agent to the desired cells. Key data from the presentation noted that the ECO Synthesis manufacturing platform: Incorporated RNA bases with common modifications used in current siRNA therapeutic assets; Achieved coupling efficiency greater than 98%; Executed the enzymatic addition of a conjugation moiety; and Confirmed lack of notable impurities typically observed in phosphoramidite chemistry synthesis. Now that Codexis has successfully achieved this important technical milestone, the Company is continuing process development to optimize yield, purity and quality with the goal of providing customers with siRNA material of comparable or better quality to phosphoramidite chemistry for preclinical testing. Codexis Launches RNA Ligase Screening and Optimization Services: Codexis also on May 14, 2024 announced the launch of its RNA Ligase Screening and Optimization Services. An overview of this new offering will be highlighted during a TIDES Talk session on Thursday, May 16, 2024. During phosphoramidite chemical synthesis of RNA, each nucleotide added to the growing oligonucleotide amplifies inherent coupling errors, leading to a decrease in the yield of the desired full-length RNA construct. By utilizing a ligation approach, multiple short, single-stranded RNA (ssRNA) fragments can be synthesized, via phosphoramidite chemistry or the ECO Synthesis manufacturing platform, then duplexed and ligated together with an ecoRNA double-stranded ligase to form the desired double-stranded RNA (dsRNA) construct. This method provides the potential for higher purity and yield, which allows for increased scalability and reduced manufacturing costs. As part of Codexis’ Center of Excellence for Enzymatic RNA Synthesis, the Company provides RNA ligase screening and optimization services, which include the custom evolution of dsRNA ligase enzyme variants, screening and protocol optimization for manufacturing and use of the dsRNA ligase, and research-grade RNA production, which can be used for future preclinical studies. Reported Earnings • May 03
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: US$0.17 loss per share (improved from US$0.34 loss in 1Q 2023). Revenue: US$17.1m (up 32% from 1Q 2023). Net loss: US$11.5m (loss narrowed 49% from 1Q 2023). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 41% per year, which means it has not declined as severely as earnings. Announcement • May 03
Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024 Codexis, Inc. reiterated financial guidance for the fiscal 2024. For the period, the company product revenues are expected to be in the range of $38 million to $42 million, excluding revenue related to PAXLOVID™. R&D revenues are expected to be in the range of $18 million to $22 million. Announcement • Apr 28
Codexis, Inc., Annual General Meeting, Jun 11, 2024 Codexis, Inc., Annual General Meeting, Jun 11, 2024, at 09:00 Pacific Standard Time. Agenda: To elect the two Class II directors nominees identified in the accompanying proxy statement to hold office until the 2027 annual meeting of stockholders; to ratify the selection by the Audit Committee of the board of directors of KPMG LLP as an independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding, advisory basis, the compensation of named executive officers; and transact such other business as may properly come before the Annual Meeting. Announcement • Apr 20
Codexis, Inc. to Report Q1, 2024 Results on May 02, 2024 Codexis, Inc. announced that they will report Q1, 2024 results After-Market on May 02, 2024 Announcement • Apr 11
Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board Codexis, Inc. announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufacturing, process development, plant operations and global supply chain management. Ms. Cobb has forty years of bio-based industry experience and is currently a business consultant for biotechnology companies. Most recently, she served as the Chief Operating Officer at GreenLight Biosciences where she led the Company’s efforts to scale their proprietary bioprocessing methods. Prior to joining GreenLight, Ms. Cobb served as Chief Operating Officer at Cobalt Technologies. Earlier in her career, Ms. Cobb held senior leadership roles at Danisco A/S and Genencor International. She holds a Master of Business Administration from the University of Rochester and Bachelor of Science degrees in Chemical Engineering, Biochemistry and Cell & Molecular Biology from the State University of New York at Buffalo. Current members include John Maraganore, PhD, founder and former Chief Executive Officer of Alnylam Pharmaceuticals; Masad Damha, PhD, Distinguished James McGill Professor at McGill University; Jim Lalonde, PhD, biotechnology consultant for start-up companies in enzyme engineering and former Senior Vice President of Research and Development at Codexis; and Carole Cobb, MBA, biotechnology consultant and former Chief Operating Officer at GreenLight Biosciences. Major Estimate Revision • Mar 06
Consensus revenue estimates increase by 12% The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from US$58.5m to US$65.4m. Forecast losses expected to reduce from -US$0.672 to -US$0.646 per share. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$6.57 unchanged from last update. Share price fell 2.2% to US$3.64 over the past week. Board Change • Mar 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Member of Strategic Advisory Board John M. Maraganore was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 29
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: US$1.12 loss per share (further deteriorated from US$0.51 loss in FY 2022). Revenue: US$70.1m (down 49% from FY 2022). Net loss: US$76.2m (loss widened 127% from FY 2022). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 5.0%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 39% per year, which means it has not declined as severely as earnings. Announcement • Feb 21
Codexis, Inc Appoints Masad Damha, PhD and Jim Lalonde, PhD to Strategic Advisory Board Codexis, Inc. announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former Chief Executive Officer of Alnylam Pharmaceuticals. This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform. Masad Damha, PhD, is the Distinguished James McGill Professor at McGill University. His research has been instrumental in the development of new therapeutic drugs based on RNA targeting and gene editing, and he has authored more than 200 publications. Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA). His FANA technology is being applied by multiple research laboratories and industries to assess and develop modified oligonucleotides against several biological targets, including cancer and infectious diseases. Dr. Damha has served as the President of both the International Society of Nucleosides, Nucleotides and Nucleic Acids and the Oligonucleotide Therapeutic Society, and currently serves on the Editorial Board of the journal Nucleic Acids Therapeutics. He received both his PhD and BSc in Organic Chemistry from McGill University. Jim Lalonde, PhD, is a biotechnology consultant for start-up companies in enzyme engineering and biotechnology. Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne. Most recently, Dr. Lalonde served as the head of the Microbial Digital Genome Engineering Business at Inscripta. Prior to Inscripta, he spent nearly 15 years at Codexis, culminating in the role of Senior Vice President of Research and Development, where he oversaw the development of more than 50 enzymes for biotherapeutics, drug manufacturing, nutrition and molecular diagnostics applications. Earlier in his career, Dr. Lalonde held leadership roles in biocatalysis and chemical development at Altus Biologics and in scientific research at Vista Chemical Company. Dr. Lalonde earned a PhD in Organic Chemistry from Texas A&M University and a BS in Chemistry from Lakehead University. Announcement • Feb 17
Codexis, Inc. Announces Not to Stand for Reelection of Jennifer Aaker as Board of Director Codexis, Inc. announced on February 13, 2024, Jennifer Aaker, Ph.D. provided notice to the board of directors of Codexis, Inc. of her intention not to stand for reelection to the Board at the expiration of her current term at the company’s 2024 Annual Meeting of Stockholders (the 2024 Annual Meeting). Dr. Aaker’s decision not to stand for reelection is not the result of any disagreement with the company on any matter relating to its operations, policies, practices or otherwise. Dr. Aaker will remain a director until the 2024 Annual Meeting. New Risk • Feb 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$19m net loss in 3 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Announcement • Feb 02
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting seqWell and Codexis, Inc. announced the creation of an engineered high-performance transposase enzyme designed to drive superior performance in sequencing applications. The co-development of this new transposase enzyme - called TnX transposase - builds upon a multi-year partnership between the two companies, leveraging Codexis' strength in enzyme engineering, and seqWell's expertise in developing tools to improve next-generation sequencing (NGS) performance. Performance data highlighting this enzyme will be presented during the Advances in Genome Biology and Technology (AGBT) General Meeting being held February 5 - 8, 2024 in Orlando, Florida. This newly engineered transposase is designed to exhibit significantly lower bias, potentially providing more uniform coverage of sequenced DNA; improved activity, converting a higher percentage of DNA to library; and improved robustness across a range of assay conditions. seqWell plans to incorporate the TnX transposase into new NGS workflow kits currently in development. Announcement • Dec 14
Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS). Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS) on December 13, 2023. Under the terms of the deal, Aldevron will receive global manufacturing and commercialization rights to the Codex® HiCap RNA Polymerase and Codexis will receive payments for near-term technical milestones, along with commercial milestones and sales-based royalties. Major Estimate Revision • Nov 10
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$61.2m to US$60.6m. Losses expected to increase from US$1.03 per share to US$1.18. Life Sciences industry in the US expected to see average net income growth of 11% next year. Consensus price target down from US$7.43 to US$5.83. Share price fell 11% to US$1.60 over the past week. Price Target Changed • Nov 07
Price target decreased by 17% to US$6.20 Down from US$7.43, the current price target is an average from 5 analysts. New target price is 256% above last closing price of US$1.74. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.51 last year. Price Target Changed • Nov 05
Price target increased by 13% to US$8.40 Up from US$7.43, the current price target is an average from 5 analysts. New target price is 335% above last closing price of US$1.93. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$1.11 next year compared to a net loss per share of US$0.51 last year. Reported Earnings • Nov 03
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: US$0.50 loss per share (further deteriorated from US$0.15 loss in 3Q 2022). Revenue: US$9.28m (down 73% from 3Q 2022). Net loss: US$34.9m (loss widened 249% from 3Q 2022). Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) also missed analyst estimates by 54%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Announcement • Nov 03
Codexis, Inc. Reiterates Earnings Guidance for the Year 2023 Codexis, Inc. reiterated earnings guidance for the year 2023. Codexis reiterated its 2023 financial guidance ranges originally issued on July 20, 2023, and reiterated on August 3, 2023, as follows: Product revenues are expected to be in the range of $30 million to $35 million, excluding enzyme sales related to PAXLOVID™. R&D revenues are expected to be in the range of $21 million to $24 million. 